Following is a list of 40 executives of publicly traded biopharma drug developers and tools/technology companies, ranked by the total value of their shares of common stock as stated on the companies’ proxy statements or Form 20-F statements. Each executive is listed with their title and company, the total value of their shares of common stock, the number of shares of common stock (by category where available), and the closing share price of their company’s stock as of the “record date” for determining shareholders entitled to notice of, and to vote at, their company’s annual meeting, with footnotes where applicable.
Unlike the first edition of this list last year (see “Top 20 Molecular Millionaires,” published in GEN October 2, 2012), all categories of shares of common stock were listed—not only the value of their shares of common stock as of the day they were tallied and recorded in filings, but shares of common stock which were exercisable or became so within a set period of time (typically 60 days) from the record date. The change reflects the fact numerous companies recorded the total number of shares of common stock for their largest shareholders—with explanations about multiple common stock categories in footnotes of the proxies or 20-F forms—in order to present a more complete picture of who owns what percentage of the companies’ stock. The change also explains why the top three on this list could better be described as molecular billionaires.
The results showed the wealthiest molecular millionaires were officers, directors, former officers and directors, or investors of mature biotechs—typically those with products on the market, and the profits that follow. Several companies in that category could boast of having multiple executives, directors, or investors on this year’s list: Regeneron Pharmaceuticals led biotechs—and all companies, for that matter—with seven, followed by Vertex Pharmaceuticals (four), Bio-Rad Laboratories and Danaher (three each), and Bristol-Myers Squibb, Life Technologies, and Mettler Toledo (two each).
The results reflect how good a year 2012 was for Regeneron and Vertex. In its proxy report, Regeneron noted the company overachieved its goals for last year, among them continued successful commercialization of Eylea (aflibercept) injection, including launch following FDA approval for a new macular edema indication; and FDA approval of Zaltrap (ziv-aflibercept) injection for IV infusion for use with Folfiri for metastatic colorectal cancer. Vertex launched Kalydeco for cystic fibrosis shortly after it gained FDA approval on August 31, 2012 and quickly racked up $171.6 million in sales, a figure expected to rise significantly this year.
Big pharmas have only a small presence on this list, with only five executives and/or investors from four such companies appearing. Ranking highest among big pharmas, at No. 14, was not a current pharma exec but a retired chairman. The CEOs of two other pharma giants—Joseph Jimenez of Novartis, and Ian C. Read of Pfizer—narrowly missed the top 40.